Table 1.

Characteristics of the included studies

Study	Subjects (T/C)	Age (T/C)	Male (T/C)	Ejection fraction, (%) (T/ C)	Interventions (T/C)	Follow-up period	Outcomes	Crude events (T/C)
O’Keefe (2007) [29]	749/734	66 ± 10/66 ± 10	63/64	32 ± 6 /32 ± 6	Eplerenone/Placebo	Mean 16 months	①all-cause mortality	①153/175
							②Hyperkalaemia(>5.5 mmol/l)	②42/22
							③Death from CV causes	③131/152
Eschalier (2013) [30]	459/400	68.1 ± 7.4/N.r.	356/N.r.	26.44 ± 4.7/N.r.	Eplerenone/Placebo	N.r	①Hyperkalaemia(>5.5 mmol/l)	①63/33
							②CV mortality+HF hospitalization	②99/141
							③Change in eGFR from baseline to final visit	③- 4.94(17.4)/-2.93(18.9)
Vadugana than (2014) [31]	444/306	65.1 ± 10.1/67.9 ± 10.7	320/242	26.7 ± 7.8/28.6 ± 8.8	MRAs/no MRAs	Mean 9.9 months	①all-cause mortality;	①101/98
							②CV mortality+HF hospitalization	②182/147
							③Death from CV causes	③78/66
Khosraviani (2014) [32]	536/1114	N.r.	N.r.	N.r.	Spironolactone/no spironolactone	2 years	all-cause mortality	79/223

Notes: T Trial Group, C Control Group, N.r. not report, MRAs mineralocorticoid receptor antagonists, CV cardiovascular, HF heart failure, CI confidence interval, eGFR estimated glomerular filtration rate